复宏汉霖(02696.HK)：汉曲优获FDA批准用于乳腺癌辅助治疗等

阿斯达克财经04-26

复宏汉霖(02696.HK) 公布，HLX02(汉曲优)获美国食品药品管理局FDA批准用于辅助治疗HER2过表达乳腺癌；治疗HER2过表达转移性乳腺癌；及治疗HER2过表达转移性胃腺癌或胃食管交界腺癌，其于美国获批的商品名为HERCESSI。据此，HLX02成为公司首个获FDA批准于美国上市的产品。该药是公司按照中国、欧盟和美国生物类似药指导原则自主开发并获中欧美三地批准的单抗生物类似药，用于...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2430213967?lang=zh_CN&edition=full","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20200928110330279_s.jpg","is_english":false,"pubTime":"2024-04-26 12:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2430213967","market":"fut","top_or_hot":-1,"title":"复宏汉霖(02696.HK)：汉曲优获FDA批准用于乳腺癌辅助治疗等","media":"阿斯达克财经","content":"<div>\n<p>复宏汉霖(02696.HK) 公布，HLX02(汉曲优)获美国食品药品管理局FDA批准用于辅助治疗HER2过表达乳腺癌；治疗HER2过表达转移性乳腺癌；及治疗HER2过表达转移性胃腺癌或胃食管交界腺癌，其于美国获批的商品名为HERCESSI。据此，HLX02成为公司首个获FDA批准于美国上市的产品。该药是公司按照中国、欧盟和美国生物类似药指导原则自主开发并获中欧美三地批准的单抗生物类似药，用于...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1345384/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复宏汉霖(02696.HK)：汉曲优获FDA批准用于乳腺癌辅助治疗等</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复宏汉霖(02696.HK)：汉曲优获FDA批准用于乳腺癌辅助治疗等\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-26 12:21 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1345384/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>复宏汉霖(02696.HK) 公布，HLX02(汉曲优)获美国食品药品管理局FDA批准用于辅助治疗HER2过表达乳腺癌；治疗HER2过表达转移性乳腺癌；及治疗HER2过表达转移性胃腺癌或胃食管交界腺癌，其于美国获批的商品名为HERCESSI。据此，HLX02成为公司首个获FDA批准于美国上市的产品。该药是公司按照中国、欧盟和美国生物类似药指导原则自主开发并获中欧美三地批准的单抗生物类似药，用于...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1345384/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1345384/latest-news/AAFN","article_id":"2430213967","we_media_id":null,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20200928110330279_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2430213967","pubTimestamp":1714105260,"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"复宏汉霖(02696.HK) 公布，HLX02(汉曲优)获美国食品药品管理局FDA批准用于辅助治疗HER2过表达乳腺癌；治疗HER2过表达转移性乳腺癌；及治疗HER2过表达转移性胃腺癌或胃食管交界腺癌，其于美国获批的商品名为HERCESSI。据此，HLX02成为公司首个获FDA批准于美国上市的产品。该药是公司按照中国、欧盟和美国生物类似药指导原则自主开发并获中欧美三地批准的单抗生物类似药，用于HER2阳性的乳腺癌辅助治疗、HER2阳性的乳腺癌及胃癌治疗。(ha/u)(港股报价延迟最少十五分钟。)AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","02696":"复宏汉霖"},"translate_title":"Henlius (02696. HK): Hanquyou has been approved by the FDA for adjuvant treatment of breast cancer, etc.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1},"content_text":"复宏汉霖(02696.HK) 公布，HLX02(汉曲优)获美国食品药品管理局FDA批准用于辅助治疗HER2过表达乳腺癌；治疗HER2过表达转移性乳腺癌；及治疗HER2过表达转移性胃腺癌或胃食管交界腺癌，其于美国获批的商品名为HERCESSI。据此，HLX02成为公司首个获FDA批准于美国上市的产品。该药是公司按照中国、欧盟和美国生物类似药指导原则自主开发并获中欧美三地批准的单抗生物类似药，用于HER2阳性的乳腺癌辅助治疗、HER2阳性的乳腺癌及胃癌治疗。(ha/u)(港股报价延迟最少十五分钟。)AASTOCKS新闻","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2430213967"}